Discovery of prognostic biomarker candidates of lacunar infarction by quantitative proteomics of microvesicles enriched plasma

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Datta, Arnab ^a,c   Chen, Christopher P ^b,c   Sze, Siu Kwan ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BIOINFORMATICS; CELL VACUOLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; LACUNAR STROKE; MALE; MASS SPECTROMETRY; MICROVESICLE; NEUROPSYCHOLOGICAL TEST; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PROGNOSIS; PROSPECTIVE STUDY; PROTEOMICS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; RISK FACTOR; WESTERN BLOTTING; AGED; BLOOD; BLOOD CLOTTING; CHEMICAL PHENOMENA; CHROMATOGRAPHY; CLUSTER ANALYSIS; DEMOGRAPHY; FOCAL ADHESION; ISOTOPE LABELING; MEMBRANE MICROPARTICLE; METABOLISM; MIDDLE AGED; PROCEDURES; STATIC ELECTRICITY; STROKE, LACUNAR;

BIOLOGICAL MARKER; PROTEOME;

AGED; BIOLOGICAL MARKERS; BLOOD COAGULATION; CELL-DERIVED MICROPARTICLES; CHROMATOGRAPHY; CLUSTER ANALYSIS; DEMOGRAPHY; FEMALE; FOCAL ADHESIONS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; ISOTOPE LABELING; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROTEOME; PROTEOMICS; STATIC ELECTRICITY; STROKE, LACUNAR;

EID: 84899698283     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094663     Document Type: Article

References (66)

1. Wardlaw JM (2011) Differing risk factors and outcomes in ischemic stroke subtypes: Focus on lacunar stroke. Future Neurol 6: 201-221.
2. Gunarathne A, Patel JV, Gammon B, Gill PS, Hughes EA, et al. (2009) Ischemic stroke in south asians: a review of the epidemiology, pathophysiology, and ethnicity-related clinical features. Stroke 40: e415-e423.
3. Rajapakse A, Rajapakse S, Sharma JC (2011) Is investigating for carotid artery disease warranted in non-cortical lacunar infarction? Stroke 42: 217-220.
4. Kirshner HS (2010) Current issues in antiplatelet therapy for stroke prevention: The importance of stroke subtypes and differences between stroke and MI patients. J Neurol 257: 1788-1797.
5. De Silva DA, Woon FP, Pin LM, Chen CP, Chang HM, et al. (2007) Intracranial large artery disease among OCSP subtypes in ethnic South Asian ischemic stroke patients. J Neurol Sci 260: 147-149. (Pubitemid 47212220)
6. Grau-Olivares M, Arboix A (2009) Mild cognitive impairment in stroke patients with ischemic cerebral small-vessel disease: A forerunner of vascular dementia? Expert Rev Neurother 9: 1201-1217.
7. Zimmermann-Ivol CG, Burkhard PR, Le Floch-Rohr J, Allard L, Hochstrasser DF, et al. (2004) Fatty acid binding protein as a serum marker for the early diagnosis of stroke: A pilot study. Mol Cell Proteomics 3: 66-72. (Pubitemid 38697105)
8. Giron P, Dayon L, Turck N, Hoogland C, Sanchez JC (2011) Quantitative analysis of human cerebrospinal fluid proteins using a combination of cysteine tagging and amine-reactive isobaric labeling. J Proteome Res 10: 249-258.
9. Bettermann K (2011) Biomarkers for stroke: in search of fingerprints. J Stroke Cerebrovasc Dis 20: 173-176.
10. Foerch C, Montaner J, Furie KL, Ning MM, Lo EH (2009) Invited article: searching for oracles? Blood biomarkers in acute stroke. Neurology 73: 393-399.
11. Jickling GC, Sharp FR (2011) Blood Biomarkers of Ischemic Stroke. Neurotherapeutics 8: 349-360.
12. Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, et al. (2001) Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res 66: 510-516. (Pubitemid 33027419)
13. Hassan A, Hunt BJ, O'Sullivan M, Parmar K, Bamford JM, et al. (2003) Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain 126: 424-432. (Pubitemid 36172746)
14. Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, et al. (2004) Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 127: 212-219. (Pubitemid 38055360)
15. Elkind MSV, Luna JM, Coffey CS, McClure LA, Liu KM, et al. (2010) The levels of inflammatory markers in the treatment of stroke study (limits): Inflammatory biomarkers as risk predictors after lacunar stroke. Int J Stroke 5: 117-125.
16. Qureshi IA, Mehler MF (2013) Towards a 'systems'-level understanding of the nervous system and its disorders. Trends Neurosci 36: 674-684.
17. Turola E, Furlan R, Bianco F, Matteoli M, Verderio C (2012) Microglial microvesicle secretion and intercellular signaling. Front Physiol 3: 149.
18. Colombo E, Borgiani B, Verderio C, Furlan R (2012) Microvesicles: novel biomarkers for neurological disorders. Front Physiol 3: 63.
19. Ceruti S, Colombo L, Magni G, Viganó F, Boccazzi M, et al. (2011) Oxygen-glucose deprivation increases the enzymatic activity and the microvesiclemediated release of ectonucleotidases in the cells composing the blood-brain barrier. Neurochemistry International 59: 259-271.
20. Adav SS, Chao LT, Sze SK (2012) Quantitative secretomic analysis of Trichoderma reesei strains reveals enzymatic composition for lignocellulosic biomass degradation. Mol Cell Proteomics 11: M111.012419.
21. Park JE, Tan HS, Datta A, Lai RC, Zhang H, et al. (2010) Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics 9: 1085-1099.
22. Datta A, Park JE, Li X, Zhang H, Ho ZS, et al. (2010) Phenotyping of an in vitro model of ischemic penumbra by iTRAQ-based shotgun quantitative proteomics. J Prot Res 9: 472-484.
23. Datta A, Jingru Q, Khor TH, Teo MT, Heese K, et al. (2011) Quantitative neuroproteomics of an in vivo rodent model of focal cerebral ischemia/ reperfusion injury reveals a temporal regulation of novel pathophysiological molecular markers. J Prot Res 10: 5199-5213.
24. Datta A, Akatsu H, Heese K, Sze SK (2013) Quantitative Clinical Proteomic Study of Autopsied Human Infarcted Brain Specimens to Elucidate the Deregulated Pathways in Ischemic Stroke Pathology. J Proteomics 91: 556-568.
25. Datta A, Qian J, Chong R, Kalaria RN, Francis P, et al. (2014) Novel pathophysiological markers are revealed by iTRAQ-based quantitative clinical proteomics approach in vascular dementia. J Proteomics 99C: 54-67.
26. De Schryver ELLM (2000) Design of ESPRIT: An international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin. Cerebrovascular Diseases 10: 147-150.
27. Narasimhalu K, Ang S, De Silva DA, Wong MC, Chang HM, et al. (2011) The prognostic effects of poststroke cognitive impairment no dementia and domainspecific cognitive impairments in nondisabled ischemic stroke patients. Stroke 42: 883-888.
28. Bonita R, Beaglehole R (1988) Modification of rankin scale: Recovery of motor function after stroke. Stroke 19: 1497-1500. (Pubitemid 19005804)
29. Narasimhalu K, Lee J, Leong YL, Ma L, De Silva DA, et al. (2013) Inflammatory markers and their association with post stroke cognitive decline. Int J Stroke.
30. A P, Association. (1994) Diagnostic and statistical manual of mental disorders-iv: American Psychiatric Association.
31. Mead GE, Lewis SC, Wardlaw JM, Dennis MS, Warlow CP (2000) How well does the Oxfordshire community stroke project classification predict the site and size of the infarct on brain imaging? J Neurol Neurosurg Psychiatry 68: 558-562. (Pubitemid 30248817)
32. Palmisano G, Jensen S, Le Bihan MC, Lainé J, McGuire JN, et al. (2012) Characterization of membrane-shed microvesicles from cytokine-stimulated β-cells using proteomics strategies. Mol Cell Proteomics 11: 230-243.
33. Kanhai DA, Visseren FLJ, Van Der Graaf Y, Schoneveld AH, Catanzariti LM, et al. (2013) Microvesicle protein levels are associated with increased risk for future vascular events and mortality in patients with clinically manifest vascular disease. Int J Cardiol 168: 2358-2363.
34. Hao P, Qian J, Ren Y, Sze SK (2011) Electrostatic repulsion-hydrophilic interaction chromatography (ERLIC) versus strong cation exchange (SCX) for fractionation of iTRAQ-labeled peptides. J Proteome Res 10: 5568-5574.
35. Huang da W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13.
36. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863-14868. (Pubitemid 29003722)
37. Smith MPW, Wood SL, Zougman A, Ho JTC, Peng J, et al. (2011) A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses. Proteomics 11: 2222-2235.
38. Yadav AK, Bhardwaj G, Basak T, Kumar D, Ahmad S, et al. (2011) A systematic analysis of eluted fraction of plasma post immunoaffinity depletion: Implications in biomarker discovery. PLoS ONE 6: art. no. e24442.
39. Chen X, Shan Q, Jiang L, Zhu B, Xi X (2013) Quantitative proteomic analysis by iTRAQ for identification of candidate biomarkers in plasma from acute respiratory distress syndrome patients. Biochemical and Biophysical Research Communications 441: 1-6.
40. Kashyap RS, Nayak AR, Deshpande PS, Kabra D, Purohit HJ, et al. (2009) Inter-alpha-trypsin inhibitor heavy chain 4 is a novel marker of acute ischemic stroke. Clinica Chimica Acta 402: 160-163.
41. Anderson L, Hunter CL (2006) Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 5: 573-588.
42. Whiteaker JR, Zhang H, Eng JK, Fang R, Piening BD, et al. (2007) Head-tohead comparison of serum fractionation techniques. J Prot Res 6: 828-836. (Pubitemid 46340186)
43. Mathivanan S, Ji H, Simpson RJ (2010) Exosomes: extracellular organelles important in intercellular communication. J Proteomics 73: 1907-1920.
44. Horstman LL, Jy W, Bidot CJ, Nordberg ML, Minagar A, et al. (2009) Potential roles of cell-derived microparticles in ischemic brain disease. Neurol Res 31: 799-806.
45. Azevedo LCP, Pedro MA, Laurindo FRM (2007) Circulating microparticles as therapeutic targets in cardiovascular diseases. Recent Patents on Cardiovascular Drug Discovery 2: 41-51. (Pubitemid 46813415)
46. Wardlaw JM, Sandercock PA, Dennis MS, Starr J (2003) Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 34: 806-812.
47. Ahmad O, Wardlaw J, Whiteley WN (2012) Correlation of levels of neuronal and glial markers with radiological measures of infarct volume in ischaemic stroke: a systematic review. Cerebrovascular Diseases 33: 47-54.
48. Whiteley W, Chong WL, Sengupta A, Sandercock P (2009) Blood markers for the prognosis of ischemic stroke: A systematic review. Stroke 40: e380-e389.
49. Ye F, Hu G, Taylor D, Ratnikov B, Bobkov AA, et al. (2010) Recreation of the terminal events in physiological integrin activation. J Cell Biol 188: 157-173.
50. Kiema T, Lad Y, Jiang P, Oxley CL, Baldassarre M, et al. (2006) The molecular basis of filamin binding to integrins and competition with talin. Molecular Cell 21: 337-347. (Pubitemid 43163529)
51. Nishimura S, Manabe I, Nagasaki M, Kakuta S, Iwakura Y, et al. (2011) In vivo imaging visualizes discoid platelet aggregations without endothelium disruption and implicates contribution of inflammatory cytokine and integrin signaling. Blood doi:10.1182/blood-2011-09-381400.
52. Bhatt DL, Topol EJ (2003) Scientific and therapeutic advances in antiplatelet therapy. Nature Review Drug Discovery 2: 15-28. (Pubitemid 37361621)
53. Resch KL, Ernst E, Matrai A, Paulsen HF (1992) Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med 117: 371-375.
54. Marti-Fabregas J, Valencia C, Pujol J, Garcia-Sanchez C, Marti-Vilalta JL (2002) Fibrinogen and the amount of leukoaraiosis in patients with symptomatic small-vessel disease. Eur Neurol 48: 185-190. (Pubitemid 44858311)
55. Jauch EC, Lindsell C, Broderick J, Fagan SC, Tilley BC, et al. (2006) Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke 37: 2508-2513. (Pubitemid 44454670)
56. Hill MD, Jackowski G, Bayer N, Lawrence M, Jaeschke R (2000) Biochemical markers in acute ischemic stroke. CMAJ 162: 1139-1140. (Pubitemid 30246286)
57. Pantoni L (2010) Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 9: 689-701.
58. Ren X, Akiyoshi K, Grafe MR, Vandenbark AA, Hurn PD, et al. (2011) Myelin specific cells infiltrate MCAO lesions and exacerbate stroke severity. Metab Brain Dis: 1-9.
59. Cho YM, Choi IS, Bian RX, Kim JH, Han JY, et al. (2008) Serum albumin at admission for prediction of functional outcome in ischaemic stroke patients. Neurol Sci 29: 445-449.
60. Idicula TT, Waje-Andreassen U, Brogger J, Naess H, Thomassen L (2009) Serum albumin in ischemic stroke patients: the higher the better. The Bergen Stroke Study. Cerebrovasc Dis 28: 13-17.
61. Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD (2001) Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 32: 553-560. (Pubitemid 32155250)
62. Hill MD, Martin RH, Palesch YY, Tamariz D, Waldman BD, et al. (2011) The Albumin in Acute Stroke Part 1 Trial: an exploratory efficacy analysis. Stroke 42: 1621-1625.
63. Nimmagadda A, Park HP, Prado R, Ginsberg MD (2008) Albumin therapy improves local vascular dynamics in a rat model of primary microvascular thrombosis: a two-photon laser-scanning microscopy study. Stroke 39: 198-204.
64. Ito Y, Nakachi K, Imai K, Hashimoto S, Watanabe Y, et al. (2005) Stability of frozen serum levels of insulin-like growth factor-I, insulin-like growth factor-II, insulin-like growth factor binding protien-3, transforming growth factor β, soluble fas, and superoxide dismutase activity for the JACC Study. J Epidemiol 15: S67-S73. (Pubitemid 41403844)
65. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, et al. (2009) Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40: 2244-2250.
66. Vizcaíno JA, Côté RG, Csordas A, Dianes JA, Fabregat A, et al. (2013) The Proteomics Identifications (PRIDE) database and associated tools: Status in 2013. Nucleic Acids Res 41: D1063-D1069.